Already tracking at $5 billion in annual sales, Enhertu has secured two new FDA approvals to treat early breast cancer. But ...
FDA approval brings Enhertu into early breast cancer treatment, boosting response before surgery and cutting recurrence risk ...
Daily Mail on MSN
Emily raised cash for cancer research as a teen but has now been given her own devastating diagnosis
Emily Harrison-Suhr, 31, was diagnosed with metastatic breast cancer five years ago after finding a strange lump in her ...
Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic ...
MedPage Today on MSN
Metastatic Breast Cancers on the Rise, U.S. Study Shows
Stage IV disease rates significantly increased in both men and women ...
InvestorsHub on MSN
Genentech highlights new breast cancer and precision oncology data ahead of ASCO 2026 (RHHBY)
Roche’s Genentech unit is emphasizing next-generation breast cancer therapies, targeted oncology combinations and ...
Evexomostat combination shows clinical benefit and favorable safety in heavily pretreated HR+/HER2− mBC patients with ...
After you’re diagnosed with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer, your doctor’s goal is to build a treatment plan that gives you the best chance of controlling your ...
Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer: Basel Wednesday, May 20, 2026, 11:00 Hrs [ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results